Pharming's Phase 3 trial results for leniolisib in children with APDS demonstrate efficacy and safety, supporting future ...

Briumvi (ublituximab) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis. In England and Wales, NICE has ...

AstraZeneca and Merck , known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA (olaparib) demonstrated sustained, ...

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive topline results of data from its Phase III clinical trial (NCT05438407) evaluating the ...

“In Canada, cancer immunotherapy for brain tumours is in early phases of development and requires proof-of-concept data. The support from Brain Cancer Canada fundraisers, donors, and philanthropists ...